该诺瓦瓦克斯疫苗在第二剂接种后 7 天对 COVID-19 的有效性为 90%。

The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second dose.

机构信息

Icahn School of Medicine at Mount Sinai, New York, New York, USA (H.S.S.).

出版信息

Ann Intern Med. 2021 Nov;174(11):JC124. doi: 10.7326/ACPJ202111160-124. Epub 2021 Nov 2.

DOI:10.7326/ACPJ202111160-124

PMID:34724399

Abstract

Heath PT, Galiza EP, Baxter DN, et al. N Engl J Med. 2021;385:1172-83. 34192426.

摘要

希思 PT，加利萨 EP，巴克斯特 DN，等。新英格兰医学杂志。2021;385:1172-83. 34192426.

相似文献

The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second dose.该诺瓦瓦克斯疫苗在第二剂接种后 7 天对 COVID-19 的有效性为 90%。

Ann Intern Med. 2021 Nov;174(11):JC124. doi: 10.7326/ACPJ202111160-124. Epub 2021 Nov 2.

In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second dose.在未感染过 COVID-19 的成年人中，第二剂接种后≥7 天，Novavax 疫苗的有效性为 90%。

Ann Intern Med. 2022 May;175(5):JC52. doi: 10.7326/J22-0028. Epub 2022 May 3.

The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d.单剂强生疫苗在 ≥14 天对中重度至重症 COVID-19 的有效性为 67%。

Ann Intern Med. 2021 Jul;174(7):JC75. doi: 10.7326/ACPJ202107200-075. Epub 2021 Jul 6.

In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.在高风险成年人中，第二剂接种后≥14 天， Moderna 疫苗对 COVID-19 的有效性为 94%。

Ann Intern Med. 2021 Mar;174(3):JC28. doi: 10.7326/ACPJ202103160-028. Epub 2021 Mar 2.

Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants.社论：首款基于蛋白的佐剂 Novavax 疫苗 Nuvaxovid（NVX-CoV2373）获批用于 SARS-CoV-2，有望提高疫苗接种率，并提供针对病毒变异株的免疫保护。

Med Sci Monit. 2022 Mar 1;28:e936523. doi: 10.12659/MSM.936523.

The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.BNT162b2（辉瑞/生物科技）疫苗在第 2 剂接种后 ≥7 天对 COVID-19 的有效率为 95%。

Ann Intern Med. 2021 Feb;174(2):JC15. doi: 10.7326/ACPJ202102160-015. Epub 2021 Feb 2.

NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.NVX-CoV2373 疫苗对住院的疗效：PREVENT-19 三期、随机、安慰剂对照试验的事后分析。

Vaccine. 2023 May 22;41(22):3461-3466. doi: 10.1016/j.vaccine.2023.04.054. Epub 2023 Apr 29.

NVX-Cov2373 Novavax Covid-19 vaccine: A further analysis of its efficacy using multiple modes of expression.NVX-Cov2373 诺瓦瓦克斯新冠病毒疫苗：使用多种表达模式对其疗效的进一步分析。

Fundam Clin Pharmacol. 2022 Dec;36(6):1125-1127. doi: 10.1111/fcp.12794. Epub 2022 May 7.

In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant).在南非，两剂牛津/阿斯利康疫苗未能预防轻症至中症 COVID-19（病例主要为 B.1.351 变异株）。

Ann Intern Med. 2021 May;174(5):JC50. doi: 10.7326/ACPJ202105180-050. Epub 2021 May 4.

Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.下一代新冠疫苗：疫苗研发机遇与应对新冠疫情的挑战

Drug Discov Ther. 2021;15(3):118-123. doi: 10.5582/ddt.2021.01058.

引用本文的文献

Challenges and Recent Advancements in COVID-19 Vaccines.新冠疫苗面临的挑战与近期进展

Microorganisms. 2023 Mar 18;11(3):787. doi: 10.3390/microorganisms11030787.

New-age vaccine adjuvants, their development, and future perspective.新型疫苗佐剂及其研发与未来展望。

Front Immunol. 2023 Feb 24;14:1043109. doi: 10.3389/fimmu.2023.1043109. eCollection 2023.

SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体、当前的新冠疫苗及其对2019冠状病毒病（COVID-19）的治疗意义

Vaccines (Basel). 2022 Sep 16;10(9):1538. doi: 10.3390/vaccines10091538.

Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.含乳化佐剂的低剂量 SARS-CoV-2 S 三聚体诱导 Th1 偏向的保护性免疫。

Int J Mol Sci. 2022 Apr 28;23(9):4902. doi: 10.3390/ijms23094902.

An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).新型冠状病毒病（COVID-19）的现有药物和预防性疫苗概述。

Cell Mol Biol Lett. 2022 May 13;27(1):38. doi: 10.1186/s11658-022-00339-3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

该诺瓦瓦克斯疫苗在第二剂接种后 7 天对 COVID-19 的有效性为 90%。

The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second dose.

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献